Episode 38: Unveiling T-Vant – Tulane’s Revolutionary Vaccine Adjuvant (RE-RELEASE)
Episode 38: Unveiling T-Vant – Tulane’s Revolutionary Vaccine Adjuvant (RE-RELEASE)
Delve into the groundbreaking world of novel vaccine adjuvants with guests Lisa Morici, PhD, Professor of Microbiology, and James McLachlan, PhD, Associate Professor of Immunology, who’s labs collaborate at the Tulane University School of Medicine. This episode spotlights their innovative vaccine adjuvant, T-Vant, detailing its conception, evolution, and why it holds a transformative edge over existing adjuvants. (And yes, vaccine companies – it IS available to license and partner!)
Discussion extends to the current vaccine landscape, exploring shifts, trends, and the critical role of advanced adjuvants like T-Vant. Guiding us through this informative journey is our frequent (and popular) host, Elaine Hamm, PhD.
Key Highlights:
- The T-Vant Advantage: Morici and McLachlan shed light on why T-Vant outperforms other adjuvants in the market.
- Vaccine Landscape: A comprehensive look at the current vaccine scenario, focusing on emerging innovations and challenges.
- Tulane’s Pioneering Role: Acknowledging Tulane’s ongoing commitment to promoting scientific discovery and advancements in health.
- Expert Opinions: Hear from our specialists about the future trajectory of vaccine development.
Your support propels our podcast; please like, share, and subscribe to BIO from the BAYOU. Your engagement enables us to produce compelling content and reach a wider listener base passionate about biotech breakthroughs.
Links:
Connect with Lisa Morici, PhD, and James McLachlan, PhD.
Connect with Elaine Hamm, PhD.
Learn about Tulane Medicine Business Development and the School of Medicine.
Check out BIO on the BAYOU and make plans to attend October 29 & 30, 2024.
Learn more about BIO from the BAYOU – the show, the upcoming event, and more!
